Navigation Links
Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Date:6/1/2013

CHICAGO and SAN FRANCISCO, June 1, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it presented a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of breast cancer.  Etirinotecan pegol is a unique, next generation, targeted topoisomerase I inhibitor currently in Phase 3 clinical development as a potential treatment for patients with locally recurrent or metastatic breast cancer.  The BEACON (BrEAst Cancer Outcomes with NKTR-102) Phase 3 Study is a randomized, open-label, international study that is evaluating single agent etirinotecan pegol in patients who have previously received an anthracycline, a taxane and capecitabine (ATC) versus a comparator arm consisting of an active single agent treatment of physician's choice (TPC).

"One of our objectives in treating metastatic breast cancer is to prospectively identify patients that will respond to specific treatments so they can achieve the optimal individualized care," said Hope Rugo , M.D., Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Comprehensive Cancer Center and Member of the BEACON Study investigator steering committee. "The goal of evaluating these important biomarkers in patients enrolled into the BEACON study is to help us understand which breast cancer patients might have the best clinical outcomes from treatment with etirinotecan pegol."

A series of assays for target-specific pharmacodynamic biomarkers for etirinotecan pegol, including the molecular target topoisomerase I, have been established and are being measured in the Phase 3 BEACON study.  The biomarkers were identified from Circulating Tumor Cell (CTC) samples which were collected prior to patient treatment.&#
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... 2014 A study using a relatively new ... look at the composition of carotid artery disease and ... treat the disease, a leading cause of stroke. ... between September 2010 and May 2012, was featured in ... the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... 2011 Delcath Systems, Inc. (Nasdaq: DCTH ) ... present at the Lazard Capital Markets, Eighth Annual Healthcare Conference ... New York, NY.  Mr. Hobbs will provide an overview of ... Attendance at this conference is by invitation only.  Delcath ...
... Today, the U.S. Food and Drug Administration (FDA) appealed ... District of Florida ruling in US vs. Franck,s Lab, ... for veterinary patients.  This lawsuit, brought by the Food ... Franck,s Lab in Ocala, Fla., alleged that the use ...
Cached Medicine Technology:Delcath to Present at the Lazard Healthcare Conference on November 15 2Delcath to Present at the Lazard Healthcare Conference on November 15 3International Academy of Compounding Pharmacists (IACP) Responds to FDA's Appeal of the U.S. District Court Ruling on Pharmacy Compounding 2International Academy of Compounding Pharmacists (IACP) Responds to FDA's Appeal of the U.S. District Court Ruling on Pharmacy Compounding 3
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... October 01, 2014 Scientists at the ... drugs that target immune system proteins has the power ... just posted details of the new study on their ... , Researchers in the UWA School of Pathology ... drugs to mice with mesothelioma with promising results. ...
(Date:10/1/2014)... Woodland Hills dental implants ... of dental specialists who treat full mouth implant cases ... Oviedo. Dr. Reshad of the Anacapa Dental Art Institute, ... two continents, will give a full-day presentation Oct. 4 ... , “These specialists want to improve their skills and, ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... 11 The situation for children,continues to worsen in ... families, many more are living in desperate conditions in ... with dead bodies, a,UNICEF report stated today., The ... from,UNICEF,s 10 offices in Myanmar. It details the most ...
... Caregivers Call for Better Care,Better Regulation, WASHINGTON, ... more than ninety ManorCare nursing homes in sixteen ... a carnation and a call to,action from quality ... call,Carlyle co-founder and Managing Director David Rubenstein to ...
... Efforts to Gain Clearance for Airlift of ... ... relief expert arrived in Myanmar earlier today to assess the,crisis situation ... 15 tons of essential medicines and medical,supplies to Yangon., "AmeriCares ...
... Kids and pros need to play smart to ... May 10 (HealthDay News) -- Every year in ... eye injuries, says the American Academy of Ophthalmology ... sports-specific eye protection properly fitted by an eye-care ...
... protection against heart disease ... and certain cancers, ARLINGTON, Va., May ... ranks of healthful whole grains, according,to an announcement this week from the ... to bear the whole grain health,claim. This will enable consumers to easily ...
... emergency team members have arrived in Myanmar and ... the region as the IRC,prepares for a possible ... all homes were destroyed in the villages I ... to clean drinking water," says the,IRC,s emergency coordinator, ...
Cached Medicine News:Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 2Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 3Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 4Health News:Advocates Make Mother's Day Push for Quality Care 2Health News:AmeriCares Relief Worker Arrives in Myanmar 2Health News:Protective Eyewear Key to Sports Safety 2Health News:FDA Approves Health Claim for Brown Rice 2Health News:FDA Approves Health Claim for Brown Rice 3Health News:FDA Approves Health Claim for Brown Rice 4Health News:FDA Approves Health Claim for Brown Rice 5Health News:International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast 2
... Clareon to practices that require an increased ... efficacy. The versatility of the Clareon System ... of treatments that would typically require multiple ... worry about obsolescence because the Clareon is ...
Standard Lipo-tubing...
... Donor Screening, Supplemental Confirmatory (Western Blot): The ... HIV-1 antigens on their surface. The cells ... IFA glass slide. Fixed, uninfected T-cells are ... or plasma sample with HIV- I antibodies ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
Medicine Products: